特宝生物股价连续4天下跌累计跌幅9.16%，华商基金旗下1只基金持2.67万股，浮亏损失20.62万元

Group 1 - The core point of the news is that TEBIO has experienced a decline in stock price, falling 0.49% to 76.58 CNY per share, with a total market capitalization of 31.259 billion CNY and a cumulative drop of 9.16% over the last four days [1] - TEBIO, established on August 7, 1996, is located in Xiamen, Fujian Province, and specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with 86.85% of its revenue coming from antiviral drugs, 12.87% from blood/cancer drugs, and 0.27% from other sources [1] Group 2 - From the perspective of fund holdings, Huashang Fund has a significant position in TEBIO, with its Huashang Innovation Medical Mixed A fund holding 26,700 shares, unchanged from the previous period, representing 4.31% of the fund's net value [2] - The Huashang Innovation Medical Mixed A fund, established on June 13, 2023, has a current size of 31.7429 million CNY, with a year-to-date return of 25.18% and a one-year return of 23.02%, ranking 3412 out of 8179 and 3511 out of 8148 respectively [2]